<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04629287</url>
  </required_header>
  <id_info>
    <org_study_id>KPCXM18/C101</org_study_id>
    <secondary_id>CTR20202022</secondary_id>
    <nct_id>NCT04629287</nct_id>
  </id_info>
  <brief_title>Safety,Tolerability, and Pharmacokinetic of KPCXM18 for Injection</brief_title>
  <official_title>A Randomized, Blind, Placebo-controlled,Single Andmultiple Ascending Dose Study to Assess the Safety,Tolerability, and Pharmacokinetic of KPCXM18 for Injection in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kunming Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kunming Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      to assess the safety,Tolerability, and pharmacokinetic of KPCXM18 for injection in healthy&#xD;
      subjects&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To explore the safety, tolerance and pharmacokinetic of KPCXM18 for injection in healthy&#xD;
      subjects by intravenous administration of different doses in single and multiple&#xD;
      administration safety, tolerance and pharmacokinetic tests, and to obtain the safe dose range&#xD;
      of the test drugs, thus providing dose design basis for phase II clinical trials.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2020</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Randomized, blind, dose-incrementing, placebo controlled</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects with abnormal vital signs</measure>
    <time_frame>through study completion, an average of 2 week</time_frame>
    <description>To evaluate the safety KPCXM 18 for Injection with placebo after multiple intravenous dose in healthy Chinese subjects in terms of abnormal vital signs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with abnormal laboratory</measure>
    <time_frame>through study completion, an average of 2 week</time_frame>
    <description>To evaluate the safety KPCXM 18 for Injection with placebo after multiple intravenous dose in healthy Chinese subjects in terms of abnormal laboratory</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with abnormal physical examination</measure>
    <time_frame>through study completion, an average of 2 week</time_frame>
    <description>To evaluate the safety KPCXM 18 for Injection with placebo after multiple intravenous dose in healthy Chinese subjects in terms of abnormal physical examination</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with abnormal electrocardiogram</measure>
    <time_frame>through study completion, an average of 2 week</time_frame>
    <description>To evaluate the safety KPCXM 18 for Injection with placebo after multiple intravenous dose in healthy Chinese subjects in terms of abnormal electrocardiogram</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with adverse events</measure>
    <time_frame>through study completion, an average of 2 week</time_frame>
    <description>To evaluate the safety KPCXM 18 for Injection with placebo after multiple intravenous dose in healthy Chinese subjects in terms of abnormal adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of KPCXM18 in plasma: Cmax</measure>
    <time_frame>Time Frame: Between Day 1 to 7 days</time_frame>
    <description>To characterize the pharmacokinetic parameters：Cmax of KPCXM18 after the first day administer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of KPCXM18 in plasma: Tmax</measure>
    <time_frame>Time Frame: Between Day 1 to 7 days</time_frame>
    <description>To characterize the pharmacokinetic parameters：Tmax of KPCXM18 after the first day administer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of KPCXM18 in plasma: AUC0-∞</measure>
    <time_frame>Time Frame: Between Day 1 to 7 days</time_frame>
    <description>To characterize the pharmacokinetic parameters： AUC0-∞ of KPCXM18 after the first day administer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of KPCXM18 in plasma:t1/2</measure>
    <time_frame>Time Frame: Between Day 1 to 7 days</time_frame>
    <description>To characterize the pharmacokinetic parameters： t1/2 of KPCXM18 after the</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of KPCXM18 in plasma: Cmax,ss</measure>
    <time_frame>Time Frame: Between Day 1 to 14 days</time_frame>
    <description>To characterize the pharmacokinetic parameters：Cmax,ss of KPCXM18 after the 14th day administer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of KPCXM18 in plasma: AUC0-∞,ss</measure>
    <time_frame>Time Frame: Between Day 1 to 14 days</time_frame>
    <description>To characterize the pharmacokinetic parameters：AUC0-∞,ss of KPCXM18 after the 14th day administer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of KPCXM18 in plasma: Tmax,ss</measure>
    <time_frame>Time Frame: Between Day 1 to 14 days</time_frame>
    <description>To characterize the pharmacokinetic parameters：Tmax,ss of KPCXM18 after the 14th day administer</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">102</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>KPCXM18 for injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>KPCXM18 ，freeze-dried powder,single and multiple ascending doses, Intravenous route</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, freeze-dried powder,single and multiple ascending doses, Intravenous route</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KPCXM18</intervention_name>
    <description>KPCXM18,blind,freeze-dried powder,ascending doses，Intravenous route</description>
    <arm_group_label>KPCXM18 for injection</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo,blind,freeze-dried powder,ascending doses，Intravenous route</description>
    <arm_group_label>KPCXM18 for injection</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. BMI between 19 and 26 kg/m2；male body weight not less than 50.0kg,female body weight&#xD;
             not less than 45.0kg ；&#xD;
&#xD;
          2. General physical examination and physical and chemical examination are qualified.&#xD;
&#xD;
          3. Volunteers can communicate well with the investigator, understand and comply with the&#xD;
             relevant requirements of the study, understand and sign the informed consent；&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any condition that might interfere with the procedures or tests in this study;&#xD;
&#xD;
          2. Drinking（more than 14 units of alcohol per week） in 6 months ;&#xD;
&#xD;
          3. Smoking (more than 10 cigarettes per day or equal amount of tobacco) within 3 months&#xD;
             (90 days) ;&#xD;
&#xD;
          4. Have special requirements on diet, or cannot follow a unified diet ;&#xD;
&#xD;
          5. Used a clinical trial drug within 3 months prior to administration ;&#xD;
&#xD;
          6. Positive blood pregnancy test of female subjects ;&#xD;
&#xD;
          7. Subjects may not be able to complete the study for other reasons or the investigator&#xD;
             considers that they should not be included .&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>yuhong huang, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Second Affiliated Hospital of Tianjin University of TCM</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>duo gao, ph.D</last_name>
    <phone>0871-68319868</phone>
    <phone_ext>3502</phone_ext>
    <email>duo.gao@kpc.com.cn</email>
  </overall_contact>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 3, 2020</study_first_submitted>
  <study_first_submitted_qc>November 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 16, 2020</study_first_posted>
  <last_update_submitted>November 17, 2020</last_update_submitted>
  <last_update_submitted_qc>November 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stroke</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

